L2C leukemia: a model of human acute leukemia.
D000367:Age Factors; D000818:Animals; D001500:BCG Vaccine; D002330:Carmustine / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000532:radiotherapy; D002551:Cerebral Ventricle Neoplasms / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004195:Disease Models, Animal; D006168:Guinea Pigs; D007114:Immunization; D007167:Immunotherapy; D007942:Leukemia, Experimental / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy*; D009163:Mycobacterium bovis / Q000276:immunology; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D013947:Thymosin / Q000627:therapeutic use
D001500:BCG Vaccine; D009607:Nitrosourea Compounds; D013947:Thymosin; D003520:Cyclophosphamide; D002330:Carmustine